Publications (34) Celia Fernández Rubio publications View referenced research data.

filter_list

2026

  1. Antileishmanial and Immunomodulatory Activity of Paclitaxel and Docetaxel Combined with Miltefosine and Paromomycin

    International journal of molecular sciences, Vol. 27, Núm. 7

  2. Leishmanicidal Action of the Peptides 19-4LF, 19-2.5 and 19-2.5LF Topically Administered on Cutaneous Lesions Caused by Leishmania major

    Pharmaceutics, Vol. 18, Núm. 3

2025

  1. Development of a High-Throughput Screening Platform and a Pathogenesis Model for Leishmania Infection Based on Mouse Hepatic Organoids

    International Journal of Molecular Sciences, Vol. 26, Núm. 24

  2. Discovery of Potential Antileishmanial Compounds Through Phenotypic Screening of an Alkaloid Library

    Molecules, Vol. 30, Núm. 21

  3. The Role of BRCT Domain from LmjPES in Leishmania major Pathogenesis

    Biomolecules, Vol. 15, Núm. 8

2024

  1. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 4

2023

  1. BRCT Domains: Structure, Functions, and Implications in Disease—New Therapeutic Targets for Innovative Drug Discovery against Infections

    Pharmaceutics, Vol. 15, Núm. 7

  2. Characterization of Leishmania Parasites Isolated from Naturally Infected Mammals

    Animals, Vol. 13, Núm. 13

  3. Leishmaniasia: gaixotasun globala. Tratamendurako hautagai berriak

    Zientziak eta Natura Zientziak: V. Ikergazte. Nazioarteko ikerketa euskaraz : 2023ko maiatzaren 17, 18 eta 19, Donostia, Euskal Herria

  4. Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease

    Pathogens, Vol. 12, Núm. 7

2022

  1. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

  2. Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential

    Parasitology Research, Vol. 121, Núm. 1, pp. 49-62

  3. The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  4. Tratamientos, vacunas III:: Comunicaciones orales 11

    ParaJournal: Revista de la Sociedad Española de Parasitología, Núm. 1, pp. 163-171

2021

  1. Discovery and validation of lmj_04_brct domain, a novel therapeutic target: Identification of candidate drugs for leishmaniasis

    International Journal of Molecular Sciences, Vol. 22, Núm. 19

  2. In leishmania major, the homolog of the oncogene pes1 may play a critical role in parasite infectivity

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  3. Potential therapeutic targets shared between leishmaniasis and cancer

    Parasitology, Vol. 148, Núm. 6, pp. 655-671

2020

  1. Chitin binding protein as a possible RNA binding protein in Leishmania parasites

    Pathogens and Disease, Vol. 78, Núm. 1

  2. LmjF.22.0810 from leishmania major modulates the TH2-type immune response and is involved in leishmaniasis outcome

    Biomedicines, Vol. 8, Núm. 11, pp. 1-17

  3. Structural characterization by scattering and spectroscopic methods and biological evaluation of polymeric micelles of poloxamines and TPGS as nanocarriers for miltefosine delivery

    International Journal of Pharmaceutics, Vol. 578